| Literature DB >> 32416059 |
Rashim Pal Singh1, Danny V Jeyaraju1, Veronique Voisin2, Rose Hurren1, Changjiang Xu2, James R Hawley1, Samir H Barghout1, Dilshad H Khan1, Marcela Gronda1, Xiaoming Wang1, Yulia Jitkova1, David Sharon1, Sanduni Liyanagae1, Neil MacLean1, Ayesh K Seneviratene1, Sara Mirali1, Adina Borenstein1, Geethu E Thomas1, Joelle Soriano1, Elias Orouji1, Mark D Minden1, Andrea Arruda1, Steven M Chan1, Gary D Bader2, Mathieu Lupien1, Aaron D Schimmer3.
Abstract
Leukemic stem cells (LSCs) rely on oxidative metabolism and are differentially sensitive to targeting mitochondrial pathways, which spares normal hematopoietic cells. A subset of mitochondrial proteins is folded in the intermembrane space via the mitochondrial intermembrane assembly (MIA) pathway. We found increased mRNA expression of MIA pathway substrates in acute myeloid leukemia (AML) stem cells. Therefore, we evaluated the effects of inhibiting this pathway in AML. Genetic and chemical inhibition of ALR reduces AML growth and viability, disrupts LSC self-renewal, and induces their differentiation. ALR inhibition preferentially decreases its substrate COX17, a mitochondrial copper chaperone, and knockdown of COX17 phenocopies ALR loss. Inhibiting ALR and COX17 increases mitochondrial copper levels which in turn inhibit S-adenosylhomocysteine hydrolase (SAHH) and lower levels of S-adenosylmethionine (SAM), DNA methylation, and chromatin accessibility to lower LSC viability. These results provide insight into mechanisms through which mitochondrial copper controls epigenetic status and viability of LSCs.Entities:
Keywords: ALR; AML; COX17; LSCs; copper
Mesh:
Substances:
Year: 2020 PMID: 32416059 DOI: 10.1016/j.stem.2020.04.010
Source DB: PubMed Journal: Cell Stem Cell ISSN: 1875-9777 Impact factor: 24.633